Monitor upcoming regulatory filings or clinical trial announcements for progress updates on the CAPTN-3 platform. The SAB formation signals strategic focus but does not alter near-term valuation without additional data.
Price Chart
Executive Summary
Purple Biotech announced the formation of a Scientific Advisory Board (SAB) composed of leading experts in immunotherapy and oncology to guide the development of its CAPTN-3 tri-specific antibody platform. The SAB includes specialists in T-cell and NK cell biology with direct experience in developing approved T-cell engager therapies.
Key Facts
- Purple Biotech established a Scientific Advisory Board (SAB) to support development of its CAPTN-3 tri-specific antibody platform.
- SAB members include Dr. Amir Horowitz (NK cell biology), Dr. Afshin Dowlati (early-phase clinical development in solid tumors), Dr. Alexander Shoushtari (melanoma and T-cell engager development), and Dr. Max S. Topp (early clinical development of blinatumomab).
- The CAPTN-3 platform is in preclinical development and focuses on masked tri-specific antibodies targeting 5T4 (IM1240) and TROP2 (IM1305).
- No financial terms, clinical data, or material agreements were disclosed in the filing.
Financial Impact
No immediate financial impact; advisory board formation is a strategic development without direct monetary implications.
Risk Factors
- CAPTN-3 remains in preclinical development with no guarantee of successful clinical translation.
- Company has limited financial resources (market cap $5M) and may require future capital raises, potentially dilutive to shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-046868 |
| Document: ea0286950-6k_purple.htm | 0001213900-26-046868 |
| Document: 0001213900-26-046868-index-headers.html | 0001213900-26-046868 |
| Document: 0001213900-26-046868-index.html | 0001213900-26-046868 |
| Document: 0001213900-26-046868.txt | 0001213900-26-046868 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 6-K | $1.74 $1.55 | ▼ −11.21% | ▼ −10.71% | $1.44 (−17.24%) |
Sep 2, 2026 4w ago | 6-K | $1.98 $1.74 | ▼ −12.12% | ▼ −11.16% | $1.44 (−27.27%) |
Aug 10, 2026 7w ago | 6-K | $1.55 $1.56 | ▲ +0.65% | ▲ +1.05% | $1.44 (−7.10%) |
Aug 7, 2026 8w ago | 6-K | $1.43 $1.50 | ▲ +4.90% | ▲ +4.50% | $1.44 (+0.70%) |
May 15, 2026 20w ago | Press Release | $3.94 $2.88 | ▼ −26.90% | ▼ −27.87% | $1.44 (−63.45%) |
Apr 27, 2026 22w ago | 6-K | $4.59 $4.22 | ▼ −8.06% | ▼ −8.46% | $1.44 (−68.63%) |
Apr 23, 2026 23w ago | 6-K | $4.55 $4.23 | ▼ −7.03% | ▼ −8.51% | $1.44 (−68.35%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.44 (−64.88%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.44 (−64.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access